Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23:660–70. https://doi.org/10.1038/s41590-022-01141-1.

Article  PubMed  PubMed Central  Google Scholar 

Mountzios G, Remon J, Hendriks LEL, García-Campelo R, Rolfo C, Van Schil P, et al. Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nat Rev Clin Oncol. 2023;20:664–77. https://doi.org/10.1038/s41571-023-00794-7.

Article  PubMed  Google Scholar 

Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7:184. https://doi.org/10.1186/s40425-019-0662-5.

Article  PubMed  PubMed Central  Google Scholar 

Mao Y, Xie H, Lv M, Yang Q, Shuang Z, Gao F, et al. The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating. Cancer Immunol Immunother. 2023;72:2483–98. https://doi.org/10.1007/s00262-023-03441-3.

Article  PubMed  PubMed Central  Google Scholar 

Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov. 2022;21:495–508. https://doi.org/10.1038/s41573-021-00259-5.

Article  PubMed  Google Scholar 

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218. https://doi.org/10.1038/s41573-018-0007-y.

Article  PubMed  Google Scholar 

De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F. Radiotherapy toxicity. Nat Rev Dis Primers. 2019;5:13. https://doi.org/10.1038/s41572-019-0064-5.

Article  PubMed  Google Scholar 

Kuderer NM, Desai A, Lustberg MB, Lyman GH. Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nat Rev Clin Oncol. 2022;19:681–97. https://doi.org/10.1038/s41571-022-00685-3.

Article  PubMed  Google Scholar 

Dall'Olio FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N, et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2022;19:75–90. https://doi.org/10.1038/s41571-021-00564-3.

Article  PubMed  Google Scholar 

Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725–41. https://doi.org/10.1038/s41571-020-0413-z.

Article  PubMed  Google Scholar 

Petroni G, Buqué A, Coussens LM, Galluzzi L. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat Rev Drug Discov. 2022;21:440–62. https://doi.org/10.1038/s41573-022-00415-5.

Article  PubMed  Google Scholar 

Petroni G, Cantley LC, Santambrogio L, Formenti SC, Galluzzi L. Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nat Rev Clin Oncol. 2022;19:114–31. https://doi.org/10.1038/s41571-021-00579-w.

Article  PubMed  Google Scholar 

Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20:662–80. https://doi.org/10.1038/s41568-020-0285-7.

Article  PubMed  Google Scholar 

Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altbürger C, et al. Tumour mutational burden: clinical utility, challenges and emerging improvements. Nat Rev Clin Oncol. 2024;21:725–42. https://doi.org/10.1038/s41571-024-00932-9.

Article  PubMed  Google Scholar 

Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345–62. https://doi.org/10.1038/s41571-021-00473-5.

Article  PubMed  Google Scholar 

Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23:445–60. https://doi.org/10.1038/s41573-024-00920-9.

Article  PubMed  PubMed Central  Google Scholar 

Meier P, Legrand AJ, Adam D, Silke J. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat Rev Cancer. 2024;24:299–315. https://doi.org/10.1038/s41568-024-00674-x.

Article  PubMed  Google Scholar 

Rodriguez-Ruiz ME, Vitale I, Harrington KJ, Melero I, Galluzzi L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat Immunol. 2020;21:120–34. https://doi.org/10.1038/s41590-019-0561-4.

Article  PubMed  Google Scholar 

Alzeibak, R, Mishchenko, TA, Shilyagina, NY, Balalaeva, IV, Vedunova, MV, Krysko DV. Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. J Immunother Cancer 2021;9. https://doi.org/10.1136/jitc-2020-001926.

Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23:487–500. https://doi.org/10.1038/s41590-022-01132-2.

Article  PubMed  Google Scholar 

Petroni G, Galluzzi L. Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents. Oncoimmunology. 2021;10:1889101. https://doi.org/10.1080/2162402x.2021.1889101.

Article  PubMed  PubMed Central  Google Scholar 

Bravetti G, Falvo P, Talarico G, Orecchioni S, Bertolini F. Metronomic chemotherapy, dampening of immunosuppressive cells, antigen presenting cell activation, and T cells. A quartet against refractoriness and resistance to checkpoint inhibitors. Cancer Lett. 2023;577:216441. https://doi.org/10.1016/j.canlet.2023.216441.

Article  PubMed  Google Scholar 

Andre N, Tsai K, Carre M, Pasquier E. Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all? Trends Cancer. 2017;3:319–25. https://doi.org/10.1016/j.trecan.2017.03.011.

Article  PubMed  Google Scholar 

Blake SJ, Stannard K, Liu J, Allen S, Yong MC, Mittal D, et al. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discov. 2016;6:446–59. https://doi.org/10.1158/2159-8290.Cd-15-0944.

Article  PubMed  Google Scholar 

Rios-Doria J, Durham N, Wetzel L, Rothstein R, Chesebrough J, Holoweckyj N, et al. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. Neoplasia. 2015;17:661–70. https://doi.org/10.1016/j.neo.2015.08.004.

Article  PubMed  PubMed Central  Google Scholar 

Chao Y, Liang C, Tao H, Du Y, Wu D, Dong Z, et al. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Sci Adv. 2020;6:eaaz4204. https://doi.org/10.1126/sciadv.aaz4204.

Article  PubMed  PubMed Central  Google Scholar 

Fu D, Wu J, Lai J, Liu Y, Zhou L, Chen L, et al. T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer. Am J Cancer Res. 2020;10:473–90.

PubMed  PubMed Central  Google Scholar 

Golchin S, Alimohammadi R, Rostami Nejad M, Jalali SA. Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model. J Cell Physiol. 2019;234:19866–74. https://doi.org/10.1002/jcp.28585.

Article  PubMed  Google Scholar 

Zhou J, Yang T, Liu L, Lu B. Chemotherapy oxaliplatin sensitizes prostate cancer to immune checkpoint blockade therapies via stimulating tumor immunogenicity. Mol Med Rep. 2017;16:2868–74. https://doi.org/10.3892/mmr.2017.6908.

Article  PubMed  Google Scholar 

Park SJ, Ye W, Xiao R, Silvin C, Padget M, Hodge JW, et al. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Oral Oncol. 2019;95:127–35. https://doi.org/10.1016/j.oraloncology.2019.06.016.

Article  PubMed  PubMed Central  Google Scholar 

Zhao Z, Liu S, Sun R, Zhu W, Zhang Y, Liu T, et al. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer. Front Immunol. 2023;14:1085476. https://doi.org/10.3389/fimmu.2023.1085476.

Article  PubMed  PubMed Central